Welcome to BioMarket Group!

Therapeutics

In this section you will find Therapeutics market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

Items 1 to 15 of 68 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction
  1. Antibodies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 542 companies plus partners who are today developing 1308 antibody drugs in 3051 developmental projects in cancer across 414 different targets. In addition, there are 4 suspended drugs and another 407 drugs where development has been ceased. Learn More

  2. Neuroendocrine Tumors Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 121 companies plus partners who are today developing 138 neuroendocrine tumor drugs in 199 developmental projects in cancer across 122 different targets. In addition, there is 1 suspended drug and another 24 drugs where development has been ceased. Learn More

  3. B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 309 companies plus partners who are today developing 424 B cell receptor pathway targeting drugs in 1700 developmental projects in cancer across 198 different targets. In addition, there are 5 suspended drugs and another 154 drugs where development has been ceased. Learn More

  4. Liver Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 260 companies plus partners who are today developing 280 drugs targeting liver cancer in development. across 221 different targets. In addition, there is 1 suspended drug and another 65 drugs where development has been ceased. Learn More

  5. Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 569 Androgen Receptor drugs in 1838 developmental projects in cancer across 228 different targets. In addition, there are 2 suspended drugs and another 258 drugs where development has been ceased. Learn More

  6. Biologicals in Oncology Drug Pipeline Update

    $3,675.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 1371 companies plus partners who are today developing 2823 biological drugs in 6088 developmental projects in cancer across 801 different targets. In addition, there are 25 suspended drugs and another 1050 drugs where development has been ceased. Learn More

  7. Ovarian Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 357 companies plus partners who are today developing 438 drugs targeting ovarian cancer in development. across 307 different targets. In addition, there are 6 suspended drugs and another 124 drugs where development has been ceased. Learn More

  8. Notch Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 335 companies plus partners who are today developing 416 Notch pathway targeting drugs in 1497 developmental projects in cancer across 232 different targets. In addition, there are 4 suspended drugs and another 236 drugs where development has been ceased. Learn More

  9. Nucleic Acid Therapies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 308 companies plus partners who are today developing 381 nucleic acid therapy drugs in 775 developmental projects in cancer across 251 different targets. In addition, there are 9 suspended drugs and another 211 drugs where development has been ceased. Learn More

  10. Bladder Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 139 companies plus partners who are today developing 152 drugs targeting bladder cancer in development. across 142 different targets. In addition, there are 3 suspended drugs and another 42 drugs where development has been ceased. Learn More

  11. ID Signaling Pathway in Oncology Drug Pipeline Update

    $750.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 117 companies plus partners who are today developing 114 ID pathway targeting drugs in 493 developmental projects in cancer across 104 different targets. In addition, there is 1 suspended drug and another 62 drugs where development has been ceased. Learn More

  12. Peptides in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 340 companies plus partners who are today developing 356 peptide drugs in 778 developmental projects in cancer across 252 different targets. In addition, there are 4 suspended drugs and another 148 drugs where development has been ceased. Learn More

  13. Prostate Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 462 companies plus partners who are today developing 469 drugs targeting prostate cancer in development. across 350 different targets. In addition, there are 4 suspended drugs and another 231 drugs where development has been ceased. Learn More

  14. IL-9 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 83 companies plus partners who are today developing 88 IL-9 pathway targeting drugs in 366 developmental projects in cancer across 67 different targets. In addition, there is 1 suspended drug and another 35 drugs where development has been ceased. Learn More

  15. TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 534 companies plus partners who are today developing 731 TNF-alpha pathway targeting drugs in 2597 developmental projects in cancer across 286 different targets. In addition, there are 5 suspended drugs and another 313 drugs where development has been ceased. Learn More

Items 1 to 15 of 68 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction

Therapeutics

In this section you will find Therapeutics market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

Items 1 to 15 of 68 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction
  1. Antibodies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 542 companies plus partners who are today developing 1308 antibody drugs in 3051 developmental projects in cancer across 414 different targets. In addition, there are 4 suspended drugs and another 407 drugs where development has been ceased. Learn More

  2. Neuroendocrine Tumors Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 121 companies plus partners who are today developing 138 neuroendocrine tumor drugs in 199 developmental projects in cancer across 122 different targets. In addition, there is 1 suspended drug and another 24 drugs where development has been ceased. Learn More

  3. B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 309 companies plus partners who are today developing 424 B cell receptor pathway targeting drugs in 1700 developmental projects in cancer across 198 different targets. In addition, there are 5 suspended drugs and another 154 drugs where development has been ceased. Learn More

  4. Liver Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 260 companies plus partners who are today developing 280 drugs targeting liver cancer in development. across 221 different targets. In addition, there is 1 suspended drug and another 65 drugs where development has been ceased. Learn More

  5. Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 569 Androgen Receptor drugs in 1838 developmental projects in cancer across 228 different targets. In addition, there are 2 suspended drugs and another 258 drugs where development has been ceased. Learn More

  6. Biologicals in Oncology Drug Pipeline Update

    $3,675.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 1371 companies plus partners who are today developing 2823 biological drugs in 6088 developmental projects in cancer across 801 different targets. In addition, there are 25 suspended drugs and another 1050 drugs where development has been ceased. Learn More

  7. Ovarian Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 357 companies plus partners who are today developing 438 drugs targeting ovarian cancer in development. across 307 different targets. In addition, there are 6 suspended drugs and another 124 drugs where development has been ceased. Learn More

  8. Notch Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 335 companies plus partners who are today developing 416 Notch pathway targeting drugs in 1497 developmental projects in cancer across 232 different targets. In addition, there are 4 suspended drugs and another 236 drugs where development has been ceased. Learn More

  9. Nucleic Acid Therapies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 308 companies plus partners who are today developing 381 nucleic acid therapy drugs in 775 developmental projects in cancer across 251 different targets. In addition, there are 9 suspended drugs and another 211 drugs where development has been ceased. Learn More

  10. Bladder Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 139 companies plus partners who are today developing 152 drugs targeting bladder cancer in development. across 142 different targets. In addition, there are 3 suspended drugs and another 42 drugs where development has been ceased. Learn More

  11. ID Signaling Pathway in Oncology Drug Pipeline Update

    $750.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 117 companies plus partners who are today developing 114 ID pathway targeting drugs in 493 developmental projects in cancer across 104 different targets. In addition, there is 1 suspended drug and another 62 drugs where development has been ceased. Learn More

  12. Peptides in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 340 companies plus partners who are today developing 356 peptide drugs in 778 developmental projects in cancer across 252 different targets. In addition, there are 4 suspended drugs and another 148 drugs where development has been ceased. Learn More

  13. Prostate Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 462 companies plus partners who are today developing 469 drugs targeting prostate cancer in development. across 350 different targets. In addition, there are 4 suspended drugs and another 231 drugs where development has been ceased. Learn More

  14. IL-9 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 83 companies plus partners who are today developing 88 IL-9 pathway targeting drugs in 366 developmental projects in cancer across 67 different targets. In addition, there is 1 suspended drug and another 35 drugs where development has been ceased. Learn More

  15. TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 534 companies plus partners who are today developing 731 TNF-alpha pathway targeting drugs in 2597 developmental projects in cancer across 286 different targets. In addition, there are 5 suspended drugs and another 313 drugs where development has been ceased. Learn More

Items 1 to 15 of 68 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction